Our mission

Liber’s mission, and unrelenting focus, has been to develop a range of therapeutic vaping products that medical and healthcare professionals could trust, and which would be considered a therapeutic intervention for smoking cessation.

While other participants in the Australian therapeutic vaping market are scrambling to comply with increasingly robust TGA standards for vaping products, Liber’s Nicovape® Q products have set those standards.

By holding true to our mission, Liber’s Nicovape® Q range of therapeutic vaping products is the default product of choice distributed by all three of Australia’s major national pharmaceutical wholesalers and, in turn, supplied by more than 3,500 pharmacies across Australia.

As it strives to achieve its mission, Liber has focused on:

• Developing a therapeutic vaping product that is capable of meeting the requirements for medical registration and a corporate desire to seek it;
• Embracing an approach to the category, corporate conduct and product standards that has gained the trust of key stakeholders, resulting in Liber establishing Nicovape® Q as the dominant legally accessed therapeutic vaping product;
• Providing comprehensive and pragmatic education for stakeholders about therapeutic vapes and how best to use them within a clinical context;
• Establishing a commercial framework to support the implementation and long-term success of therapeutic vapes as a genuine clinical alternative for smoking cessation; and
• Being at the forefront of driving alignment with many key stakeholders in the medical and public health communities, as well as the pharmacy channel.